Related Experiment Videos
Effect of atenolol and labetalol on serum lipids
S B Siwach1, S S Dahiya, S Seth
1Dept. of Med & Biochem, Medical College, Rohtak.
Insights
Atenolol treatment for hypertension worsened lipid profiles, indicating increased atherogenicity. Labetalol therapy did not significantly alter lipid profiles in hypertensive patients.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Clinical Therapeutics
Background:
- Hypertension is a major risk factor for cardiovascular disease.
- Lipid profile alterations are key indicators of atherogenicity.
- Atenolol and labetalol are commonly prescribed antihypertensive medications.
Purpose of the Study:
- To compare the effects of atenolol and labetalol on lipid profiles in hypertensive patients.
- To assess the atherogenicity associated with atenolol versus labetalol therapy.
Main Methods:
- A 12-week treatment study involving hypertensive patients.
- Analysis of lipid profiles (e.g., cholesterol, triglycerides) before and after treatment.
- Comparison of lipid profile changes between atenolol and labetalol groups.
Main Results:
- Atenolol treatment led to adverse changes in lipid profiles, suggesting increased atherogenicity.
- Labetalol therapy showed no significant alterations in the lipid profiles of patients.
- The study identified differential impacts of the two antihypertensive drugs on cardiovascular risk markers.
Conclusions:
- Atenolol may increase cardiovascular risk due to negative effects on lipid profiles.
- Labetalol appears to be a safer alternative regarding lipid profile management in hypertensive individuals.
- Further research is warranted to explore the long-term implications of these findings.
Abstract:
Adverse alterations in lipid profile suggesting higher atherogenicity were observed following 12 weeks treatment with atenolol in patients of hypertension. No significant alterations in lipid profile were observed with labetalol therapy.